GlassScriptPhysician profile
Ambarish Gopal
NPI 1205008026
$2,626.55
in general payments reported to CMS, 2019-2025
32 companies · $32.73 in 2025
The $32.73 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $88.23 · 2021: $610 · 2022: $689 · 2023: $467 · 2024: $254 · 2025: $32.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $279.56 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $277.05 | 2022-2024 | Verquvo |
| Heartflow, INC. | $256.23 | 2019-2024 | Ffrct |
| Amgen INC. | $226.48 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.84 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $162.32 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.42 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $96.09 | 2024 | Arcalyst |
| Novo Nordisk INC | $93.75 | 2022-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $76.21 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $63.57 | 2019 | |
| Esperion Therapeutics, INC. | $60.54 | 2021-2023 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $60.26 | 2021-2024 | Camzyos |
| Astellas Pharma US INC | $51.16 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $45.21 | 2022-2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $45.15 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.66 | 2019 | |
| Ge Healthcare | $34.57 | 2019-2021 | |
| Bardy Diagnostics, INC. | $30.39 | 2019-2020 | |
| Daiichi Sankyo INC. | $29.77 | 2023 | Injectafer |
| Tactile Systems Technology INC | $29.44 | 2022 | |
| Pfizer INC. | $28.59 | 2022 | |
| Abbott Laboratories | $24.90 | 2021 | |
| Edwards Lifesciences Corporation | $24.61 | 2022 | |
| Chiesi USA, INC. | $20.45 | 2023 | Kengreal, Cleviprex |
| Baxter Healthcare | $20.35 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $18.09 | 2023 | |
| Cleerly, INC. | $16.86 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Integra Lifesciences Corporation | $15.87 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| G Medical Diagnostic Services, INC. | $13.26 | 2023 | Cardiac Monitoring Suite |
| Itamar Medical INC | $10.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambarish Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.